Zymeworks Inc. (ZYME) Financial Ratios
12 years of historical data (2014–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: 0.98
30Y Low1.0·High1.0
P/FCF
N/A
—
5yr avg: 3.92
30Y Low3.9·High20.6
P/B Ratio
↑
6.49
↑+95% vs avg
5yr avg: 3.34
30Y Low1.0·High7.4
ROE
↑
-26.7%
-18% vs avg
5yr avg: -22.6%
30Y Low-290%·High34%
Debt/EBITDA
N/A
—
5yr avg: 0.20
30Y Low0.2·High0.2
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
ZYME Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Zymeworks Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.7B | $2.0B | $1.1B | $715M | $513M | $854M | $2.4B | $1.7B | $427M | $162M | — |
| Enterprise Value | $1.7B | $2.0B | $1.1B | $585M | $140M | $685M | $2.1B | $1.6B | $385M | $126M | — |
| P/E Ratio → | -21.43 | — | — | — | 4.14 | — | — | — | — | — | — |
| P/S Ratio | 16.07 | 18.72 | 14.56 | 9.41 | 1.24 | 32.03 | 61.13 | 58.51 | 8.05 | 3.13 | — |
| P/B Ratio | 6.49 | 7.39 | 3.28 | 1.54 | 1.04 | 3.43 | 5.81 | 7.04 | — | 1.39 | — |
| P/FCF | — | — | — | — | 3.92 | — | — | — | 20.57 | — | — |
| P/OCF | — | — | — | — | 3.56 | — | — | — | 17.66 | 739.24 | — |
P/E links to full P/E history page with 30-year chart
ZYME EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 18.50 | 13.93 | 7.69 | 0.34 | 25.67 | 55.14 | 54.39 | 7.26 | 2.43 | — |
| EV / EBITDA | — | — | — | — | 0.98 | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | 1.07 | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | 1.07 | — | — | — | 18.54 | — | — |
ZYME Profitability
Margins and return-on-capital ratios measuring operating efficiency
Zymeworks Inc. earns an operating margin of -87.3%. Operating margins have expanded from -181.6% to -87.3% over the past 3 years, signaling improving operational efficiency. A negative ROE of -26.7% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 100.0% | -88.1% | 100.0% | 100.0% | -338.7% | -296.3% | -7.4% | 20.5% | -222.9% |
| Operating Margin | -87.3% | -87.3% | -179.7% | -181.6% | 31.6% | -808.2% | -481.3% | -512.1% | -62.5% | -17.4% | -343.9% |
| Net Profit Margin | -76.6% | -76.6% | -160.8% | -156.1% | 30.1% | -794.0% | -463.5% | -492.3% | -68.9% | -20.1% | -307.1% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -26.7% | -26.7% | -30.5% | -24.8% | 33.5% | -64.3% | -55.1% | -289.7% | — | -16.6% | -248.2% |
| ROA | -20.0% | -20.0% | -23.5% | -19.3% | 24.0% | -45.7% | -39.8% | -47.5% | -19.4% | -9.2% | -57.7% |
| ROIC | -25.9% | -25.9% | -32.9% | -45.6% | 98.0% | -126.3% | -93.5% | -91.4% | — | -17.4% | -1528.4% |
| ROCE | -27.3% | -27.3% | -30.5% | -25.6% | 30.0% | -56.0% | -50.8% | -60.5% | -20.0% | -9.2% | -79.1% |
ZYME Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $41M exceeds total debt of $18M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.07 | 0.07 | 0.05 | 0.06 | 0.06 | 0.13 | 0.02 | 0.03 | — | 0.00 | 0.49 |
| Debt / EBITDA | — | — | — | — | 0.20 | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.09 | -0.14 | -0.28 | -0.76 | -0.68 | -0.57 | -0.49 | — | -0.31 | -1.33 |
| Net Debt / EBITDA | — | — | — | — | -2.62 | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | -2.85 | — | — | — | -2.03 | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — | -200.99 | -6.96 | -39.93 |
Net cash position: cash ($41M) exceeds total debt ($18M)
ZYME Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Zymeworks Inc.'s current ratio of 5.52x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 7.41x to 5.52x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.52 | 5.52 | 3.40 | 7.41 | 5.70 | 4.01 | 5.31 | 3.78 | 6.82 | 6.30 | 2.81 |
| Quick Ratio | 5.52 | 5.52 | 3.40 | 7.41 | 5.70 | 4.01 | 5.31 | 3.78 | 6.82 | 6.30 | 2.81 |
| Cash Ratio | 5.41 | 5.41 | 2.56 | 6.71 | 5.15 | 3.52 | 4.98 | 3.62 | 6.68 | 5.99 | 2.43 |
| Asset Turnover | — | 0.31 | 0.16 | 0.13 | 0.64 | 0.07 | 0.07 | 0.08 | 0.22 | 0.39 | 0.12 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 15.98 | 266.99 | 93.53 | 29.56 | 213.61 | 143.31 | 26.99 | 2.46 | 16.43 | 142.80 |
ZYME Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Zymeworks Inc. returns 2.4% to shareholders annually primarily through share buybacks.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | 24.2% | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | 25.5% | — | — | — | 4.9% | — | — |
| Buyback Yield | 2.4% | 2.1% | 2.7% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Total Shareholder Yield | 2.4% | 2.1% | 2.7% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Shares Outstanding | — | $75M | $76M | $69M | $65M | $52M | $50M | $38M | $29M | $21M | $20M |
Peer Comparison
Compare ZYME with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 ZYMEYou | $2B | -21.4 | — | — | 100.0% | -87.3% | -26.7% | -25.9% | — |
 IMVT | $7B | -12.8 | — | — | — | — | -64.8% | — | — |
 RCUS | $2B | -7.4 | — | — | 96.0% | -156.3% | -63.3% | -64.1% | — |
 MRUS | $7B | -26.9 | — | — | 37.2% | -753.0% | -41.4% | -74.6% | — |
 AGIO | $2B | -4.8 | — | — | 78.7% | -873.9% | -30.2% | -26.3% | — |
 TPST | $5M | -0.2 | — | — | — | — | -203.6% | -352.0% | — |
 ABBV | $383B | 91.4 | 15.8 | 21.5 | 70.2% | 32.8% | 6214.7% | 23.9% | 2.4 |
 ARVN | $495M | -6.0 | — | — | 98.0% | -43.8% | -16.2% | -22.4% | — |
 BCAB | $5M | -0.1 | — | — | 100.0% | -2965.3% | — | — | — |
 AGEN | $125M | -882.4 | — | — | 29.6% | -18.0% | — | — | — |
 XNCR | $927M | -10.2 | — | — | 91.6% | -141.4% | -14.0% | -16.3% | — |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 12 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
ZYME — Frequently Asked Questions
Quick answers to the most common questions about buying ZYME stock.
What is Zymeworks Inc.'s P/E ratio?
Zymeworks Inc.'s current P/E ratio is -21.4x. The historical average is 4.1x.
What is Zymeworks Inc.'s ROE?
Zymeworks Inc.'s return on equity (ROE) is -26.7%. The historical average is -74.6%.
Is ZYME stock overvalued?
Based on historical data, Zymeworks Inc. is trading at a P/E of -21.4x. Compare with industry peers and growth rates for a complete picture.
What are Zymeworks Inc.'s profit margins?
Zymeworks Inc. has 100.0% gross margin and -87.3% operating margin.